Inter-attack serum GFAP and NfL remain stable over 9 years in AQP4 IgG NMOSD
- 10 July 2026
- journal article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (10) , 918-922
Abstract
Background and objectives: Disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum disease (AQP4-IgG NMOSD) is considered relapse-driven although subclinical injury has been suggested by neuroimaging and visual pathway assessments. We investigated longitudinal changes in serum glial fibrillar acidic protein (sGFAP) and neurofilament light chain (sNfL) during relapse-free periods. Methods: We conducted a retrospective longitudinal study (2008–2025) at a UK national referral centre for NMOSD. Patients with ≥3 serum samples collected over ≥3 years were included; samples within 3 months of relapses were excluded. Longitudinal changes in sGFAP and sNfL were assessed using linear mixed-effects models with random intercepts and generalised estimating equations, adjusting for age, sex and time. Results: 40 patients (87.5% females; 162 samples; median onset age 40.1 years) and 28 matched controls were included. Over the course of four measurements and a median sampling over 9 years, stability was observed in sGFAP levels (99.2 pg/mL at 0–2.5 years (95% CI 84.2 to 117.0) to 90.3 pg/mL at 7.5–10 years (95% CI 74.7 to 109.0), p=0.65) and sNfL levels (12.0 pg/mL at 0–2.5 years (95% CI 10.8 to 13.3) to 10.4 pg/mL (9.1 to 11.8) at 7.5–10 years, p=0.12) after adjustment for covariates. Discussion: In this longitudinal study, mean sGFAP and sNfL levels remained stable over 9 years of sequential measurements during relapse-free periods, supporting the relapse-driven nature of NMOSD pathology.Keywords
This publication has 15 references indexed in Scilit:
- Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSDJournal of Neurology, 2025
- Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG–Positive Neuromyelitis Optica Spectrum DisorderJAMA Neurology, 2025
- Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre studyJournal of Neurology, Neurosurgery & Psychiatry, 2024
- Relapse-Independent disease activity in neuromyelitis optica spectrum disorder: A systematic reviewMultiple Sclerosis and Related Disorders, 2024
- Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responsesNature Communications, 2023
- A comprehensive review of the advances in neuromyelitis optica spectrum disorderAutoimmunity Reviews, 2023
- Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorderJournal of Neurology, Neurosurgery & Psychiatry, 2023
- Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple SclerosisJAMA Neurology, 2023
- Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorderMultiple Sclerosis Journal, 2021
- Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse MyelitisArchives of Neurology, 2008